The 2018 Access to Medicine Index analyses the actions of 20 pharmaceutical companies across 69 metrics in 106 low- and middle-income countries and for 77 diseases, conditions and pathogens. Here you find the three key findings from 2018 and a selection of leading graphics from the full report.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |